Deutsche Bank AG has re-created a pledge over 98,400,000 equity shares of Piramal Pharma Limited , representing 7.39% of the issued and paid-up share capital on a fully diluted basis.

The disclosure was filed with the stock exchanges on August 26, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The re-pledge restores the total encumbrance held by the bank to 238,663,700 shares, or 17.93% of the total share capital.

Transaction Details

The borrower, CA Alchemy Investments, initially pledged 238,663,700 shares (17.93%) in favor of Deutsche Bank AG, Mumbai Branch, acting as the onshore security agent for lenders including Barclays Bank PLC and Nomura Singapore Limited. This initial pledge was disclosed on May 30, 2024.

On August 17, 2026, the bank released 98,400,000 shares (7.39%) to facilitate a 'Permitted Sale Transaction' as defined in the facility agreement dated February 22, 2024. Following this release, the borrower re-created the pledge over the same block of shares on August 24, 2026.

Security Structure

Deutsche Bank AG holds the pledge in its capacity as pledgee and does not hold any beneficial interest in the shares. The offshore security agent, Deutsche Bank AG, Singapore Branch, continues to hold security interest over all shares of the borrower held by its shareholders pursuant to a deed of fixed and floating charge dated March 11, 2024.

DBX Advisors LLC holds a nominal stake of 1,317 equity shares, aggregating to approximately 0.00% of the target company's shareholding as of the disclosure date.

Piramal Pharma Limited released its sustainability report for FY26, disclosing a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions against the FY22 baseline. The company achieved its lowest-ever emissions levels while generating total revenue of ₹8,869 crore.

The report covers operations from April 1, 2025, to March 31, 2026, across Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare. DNV Business Assurance India Pvt Ltd provided independent limited assurance on key disclosures.

Financial and Operational Performance

Revenue from operations stood at ₹8,869.08 crore, down from ₹9,151.18 crore in FY25. EBITDA was ₹1,134.92 crore, compared to ₹1,579.64 crore in the prior year. The company reported a net loss of ₹325.94 crore, reversing a net profit of ₹91.13 crore in FY25.

Interest payments fell to ₹296.35 crore from ₹438.40 crore. Employee wages and benefits rose to ₹2,415.92 crore from ₹2,307.47 crore.

Environmental Impact

Renewable sources met 41% of total energy consumption. Total energy mix reached 14,20,663 GJ, with renewable/green energy contributing 5,80,730 GJ. Green fuels accounted for 52% of the overall fuel mix.

Scope 1 emissions were 47,796 tCO₂e, while location-based Scope 2 emissions were 92,626 tCO₂e. Market-based Scope 2 emissions were 62,412 tCO₂e. Scope 3 emissions totaled 6,48,835 tCO₂e.

What the Numbers Show

Scope 3 emissions represent the vast majority of the company's carbon footprint. At 6,48,835 tCO₂e, indirect value chain emissions are nearly six times higher than the combined 1,40,422 tCO₂e of direct and location-based indirect emissions. This concentration highlights that future decarbonisation efforts will depend heavily on supplier engagement rather than just internal operational changes.

Social and Governance Metrics

The company maintained zero data breaches and zero fatalities over the last five years. Women constitute 20.1% of the global workforce and 30% of the Board. Customer satisfaction scores were 85% for Piramal Pharma Solutions and 87% for Piramal Critical Care.

CSR expenditure rose to ₹8.98 crore from ₹5.34 crore, impacting approximately 1.8 million people across 112 aspirational districts.